American Shared Hospital Services (AMS) 10-K 1 Apr 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 01, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744825
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,361,000
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$8,683,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$1,059,000	$1,909,000
Restricted cash	50,000	50,000
Certificate of deposit	9,000,000	0
Trade accounts receivable, net of allowance for doubtful accounts of $100,000 in 2014 and 2013	3,192,000	4,522,000
Other receivables	131,000	143,000
Prepaid expenses and other current assets	448,000	740,000
Current deferred tax assets	367,000	342,000
Total current assets	14,247,000	7,706,000
PROPERTY AND EQUIPMENT, net	50,036,000	51,381,000
CERTIFICATE OF DEPOSIT	0	9,000,000
INVESTMENT IN EQUITY SECURITIES	2,709,000	2,701,000
OTHER ASSETS	536,000	954,000
TOTAL ASSETS	67,528,000	71,742,000
CURRENT LIABILITIES
Accounts payable	421,000	572,000
Employee compensation and benefits	179,000	204,000
Other accrued liabilities	763,000	2,238,000
Current portion of long-term debt	2,005,000	4,804,000
Current portion of capital leases	4,103,000	3,967,000
Advances on line of credit	8,780,000	0
Total current liabilities	16,251,000	11,785,000
LONG-TERM DEBT, less current portion	8,586,000	10,740,000
LONG-TERM CAPITAL LEASES, less current portion	12,190,000	12,950,000
ADVANCES ON LINE OF CREDIT	0	8,840,000
DEFERRED REVENUE, less current portion	874,000	0
DEFERRED INCOME TAXES	3,473,000	3,372,000
COMMITMENTS AND CONTINGENCIES (See Note 12)
SHAREHOLDERS’ EQUITY
Common stock, no par value Authorized - 10,000,000 shares; Issued and outstanding shares - 5,361,000 in 2014 and 4,609,000 in 2013	10,376,000	8,578,000
Additional paid-in capital	5,508,000	4,990,000
Accumulated other comprehensive loss	0	-442,000
Retained earnings	5,542,000	6,494,000
Total equity- American Shared Hospital Services	21,426,000	19,620,000
Non-controlling interests in subsidiaries	4,728,000	4,435,000
Total shareholders’ equity	26,154,000	24,055,000
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$67,528,000	$71,742,000

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts (in dollars)	$100,000	$100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,361,000	4,609,000
Common stock, shares outstanding	5,361,000	4,609,000

CONSOLIDATED_STATEMENT_OF_OPER

CONSOLIDATED STATEMENT OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Medical services	$15,417,000	$17,584,000	$17,048,000
Revenue	15,417,000	17,584,000	17,048,000
Costs of revenue:
Maintenance and supplies	1,691,000	1,791,000	1,529,000
Depreciation and amortization	6,171,000	6,309,000	5,965,000
Other direct operating costs	2,276,000	2,540,000	2,624,000
Costs of revenue	10,138,000	10,640,000	10,118,000
Gross margin	5,279,000	6,944,000	6,930,000
Selling and administrative expense	3,630,000	4,025,000	4,045,000
Interest expense	1,699,000	1,799,000	2,155,000
Operating (loss) income	-50,000	1,120,000	730,000
(Loss) on sale of subsidiary	-572,000	0	0
Gain (loss) foreign currency transactions	161,000	-1,174,000	132,000
Interest and other income	28,000	25,000	58,000
(Loss) income before income taxes	-433,000	-29,000	920,000
Income tax expense	129,000	84,000	107,000
Net (loss) income	-562,000	-113,000	813,000
Less: net income attributable to non-controlling interests	-390,000	-199,000	-775,000
Net (loss) income attributable to American Shared Hospital Services	($952,000)	($312,000)	$38,000
Net (loss) income per share attributable to American Shared Hospital Services:
(Loss) earnings per common share- basic (in dollars per share)	($0.19)	($0.07)	$0.01
(Loss) earnings per common share- diluted (in dollars per share)	($0.19)	($0.07)	$0.01

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net (loss) income attributable to American Shared Hospital Services	($952,000)	($312,000)	$38,000
Other comprehensive income (loss):
Foreign currency translation adjustments	779,000	-142,000	-637,000
Total comprehensive (loss)	-173,000	-454,000	-599,000
Less comprehensive (loss) attributable to the non-controlling interest	337,000	-57,000	-280,000
Comprehensive income (loss) attributable to American Shared Hospital Services	($510,000)	($397,000)	($319,000)

CONSOLIDATED_STATEMENT_OF_SHAR

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Noncontrolling Interest [Member]
Balances at Dec. 31, 2011	$25,171,000	$8,606,000	$4,828,000	$0	$6,768,000	$20,202,000	$4,969,000
Balances (in shares) at Dec. 31, 2011		4,611,000
Repurchase of common stock	-28,000	-28,000		0	0	-28,000	0
Repurchase of common stock (in shares)	-9,000	-9,000
Stock based compensation expense	74,000	0	74,000	0	0	74,000	0
Stock based compensation expense (in shares)		4,000
Non-controlling interest investment in subsidiaries	217,000	0	0	0	0	0	217,000
Cumulative translation adjustment	-637,000	0	0	-357,000	0	-357,000	-280,000
Cash distributions to non-controlling interests	-780,000	0	0	0	0	0	-780,000
Net (loss) income	813,000	0	0	0	38,000	38,000	775,000
Balances at Dec. 31, 2012	24,830,000	8,578,000	4,902,000	-357,000	6,806,000	19,929,000	4,901,000
Balances (in shares) at Dec. 31, 2012		4,606,000
Stock based compensation expense	88,000	0	88,000	0	0	88,000	0
Stock based compensation expense (in shares)		3,000
Non-controlling interest investment in subsidiaries	184,000	0	0	0	0	0	184,000
Cumulative translation adjustment	-142,000	0	0	-85,000	0	-85,000	-57,000
Cash distributions to non-controlling interests	-792,000	0	0	0	0	0	-792,000
Net (loss) income	-113,000	0	0	0	-312,000	-312,000	199,000
Balances at Dec. 31, 2013	24,055,000	8,578,000	4,990,000	-442,000	6,494,000	19,620,000	4,435,000
Balances (in shares) at Dec. 31, 2013		4,609,000
Repurchase of common stock	-2,000	-2,000		0	0	-2,000	0
Repurchase of common stock (in shares)	-1,000	-1,000
Stock based compensation expense	373,000	0	373,000	0	0	373,000	0
Stock based compensation expense (in shares)		3,000
Private placement common stock	1,800,000	1,800,000	0	0	0	1,800,000	0
Private placement common stock (in shares)		750,000
Fair value of warrants issued with promissory notes	145,000	0	145,000	0	0	145,000	0
Non-controlling interest investment in subsidiaries	517,000	0	0	0	0	0	517,000
Cumulative translation adjustment	779,000	0	0	442,000	0	442,000	337,000
Cash distributions to non-controlling interests	-951,000	0	0	0	0	0	-951,000
Net (loss) income	-562,000	0	0	0	-952,000	-952,000	390,000
Balances at Dec. 31, 2014	$26,154,000	$10,376,000	$5,508,000	$0	$5,542,000	$21,426,000	$4,728,000
Balances (in shares) at Dec. 31, 2014		5,361,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES
Net (loss) income	($562,000)	($113,000)	$813,000
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	6,383,000	6,410,000	6,096,000
(Gain) loss on disposal of assets	-1,000	20,000	3,000
Loss on sale of subsidiary	572,000	0	0
Deferred income tax	76,000	59,000	25,000
(Gain) loss on foreign currency transactions	-161,000	1,174,000	-132,000
Stock-based compensation expense	138,000	88,000	74,000
Other non-cash items	107,000	0	0
Changes in operating assets and liabilities:
Receivables	1,069,000	-643,000	655,000
Prepaid expenses and other assets	11,000	58,000	-316,000
Accounts payable and accrued liabilities	-859,000	1,023,000	-349,000
Net cash from operating activities	6,773,000	8,076,000	6,869,000
INVESTING ACTIVITIES
Payment for purchase of property and equipment	-5,212,000	-1,710,000	-6,634,000
Investment in equity securities	-8,000	-14,000	-31,000
Proceeds from sale of subsidiary	768,000	0	0
Net cash used in investing activities	-4,452,000	-1,724,000	-6,665,000
FINANCING ACTIVITIES
Principal payments on long-term debt	-3,263,000	-3,523,000	-6,818,000
Principal payments on capital leases	-4,429,000	-3,476,000	-3,732,000
Proceeds from long-term debt financing on property and equipment	2,625,000	1,298,000	9,219,000
Advances on line of credit	1,140,000	369,000	1,300,000
Payments on line of credit	-1,200,000	-79,000	-600,000
Capital contributions from non-controlling interests	117,000	184,000	217,000
Distributions to non-controlling interests	-951,000	-792,000	-780,000
Private placements of common stock	1,800,000	0	0
Common stock repurchase	-2,000	0	-28,000
Proceeds from promissory notes	1,000,000	0	0
Net cash used in financing activities	-3,163,000	-6,019,000	-1,222,000
Net change in cash and cash equivalents	-842,000	333,000	-1,018,000
Effect of changes in foreign exchange rates on cash	-8,000	12,000	2,000
CASH AND CASH EQUIVALENTS, beginning of year	1,909,000	1,564,000	2,580,000
CASH AND CASH EQUIVALENTS, end of year	1,059,000	1,909,000	1,564,000
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	2,070,000	2,116,000	2,352,000
Cash paid for income taxes	41,000	44,000	158,000
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of equipment with capital lease financing	3,709,000	3,478,000	264,000
Warrants issued with promissory notes	145,000	0	0
Nonmonetary equipment trade-in	700,000	0	0
Equipment relieved in sale of subsidiary	-4,921,000	0	0
Other assets relieved in sale of subsidiary	-826,000	0	0
Debt relieved in sale of subsidiary	5,181,000	0	0
Other liabilities relieved in sale of subsidiary	14,000	0	0
Net equity relieved in sale of subsidiary	1,351,000	0	0
OCI released to net income in sale of subsidiary	-779,000	0	0
Investment released to net income in sale of subsidiary	($1,360,000)	$0	$0

BUSINESS_AND_BASIS_OF_PRESENTA

BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Business and Basis of Presentation
	Business – These financial statements include the accounts of American Shared Hospital Services (the “Company”) and its subsidiaries as follows: The Company wholly-owns the subsidiaries OR21, Inc. (“OR21”); MedLeader.com, Inc. (“MedLeader”), and American Shared Radiosurgery Services (“ASRS”). The Company is also the majority owner of Long Beach Equipment, LLC (“LBE”). ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiaries GK Financing U.K., Limited (“GKUK”), and Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”). GKF is also the majority-owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”), Jacksonville GK Equipment, LLC (“JGKE”) and EWRS, LLC (“EWRS”), which, prior to its sale in June 2014, wholly-owned the subsidiary, EWRS Tibbi Cihazlar Ticaret Ltd Sti (“EWRS Turkey”).
	The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. During 2014 GKF provided Gamma Knife units to eighteen medical centers in the United States in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Texas, Washington and Wisconsin, and two medical centers in Turkey, in the cities of Adana and Istanbul.
	The Company also provided radiation therapy and related equipment directly to a medical center in Massachusetts and one in Adana, Turkey during 2014.
	The Company has formed the subsidiaries GKUK, GKPeru, EWRS, EWRS Turkey, for the purposes of expanding its business internationally into the United Kingdom, Peru and Turkey; LBE to provide proton beam therapy services in Long Beach, California; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida. AGKE and EWRS Turkey began operation in the second quarter 2011 and JGKE began operation in the fourth quarter 2011. GKPeru is expected to begin operation in 2015. GKUK is inactive and LBE is not expected to generate revenue in the next two years. The Company sold EWRS Turkey on June 10, 2014.
	OR21 will provide the product “The Operating Room for the 21st CenturySM”, which is currently under development.
	MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses and other healthcare workers. This subsidiary is not operational at this time.
	All significant intercompany accounts and transactions have been eliminated in consolidation.

ACCOUNTING_POLICIES

ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Accounting Policies
	Use of estimates in the preparation of financial statements – In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the allowance for doubtful accounts, estimated useful lives of fixed assets and its salvage values, revenues and costs of sales for turn-key and revenue sharing arrangements, and the carrying value of its Mevion investment.  Actual results could differ from those estimates.
	Advertising costs – The Company expenses advertising costs as incurred. Advertising costs were $155,000, $119,000, and $103,000 during the years ended December 31, 2014, 2013, and 2012, respectively. Advertising costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of operations.
	Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.
	Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations.
	Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. Currently much of the Company’s cash is invested in a certificate of deposit. The Company has not experienced any losses and believes it is not exposed to any significant credit risk on cash, cash equivalents and securities. The Company monitors the financial condition of the financial institutions it uses on a regular basis.
	All of the Company’s revenue was provided by twenty and nineteen customers in 2014 and 2013, and these customers constitute accounts receivable at December 31, 2014 and 2013, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.
	Accounts receivable and doubtful accounts – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for probable losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are recorded as revenue when received.
	Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. The Company also presents the consolidated net income and the portion of the consolidated net income and other comprehensive income allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations and comprehensive income (loss).
	Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 15 years, and after accounting for salvage value on the equipment where indicated. Salvage value is based on the estimated fair value of the equipment at the end of its useful life. The Company capitalized interest of $371,000, $390,000, and $196,000 in 2014, 2013, and 2012, respectively, as costs of medical equipment.
	The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2014, the Company held equipment under operating lease contracts with customers with an original cost of $82,151,000 and accumulated depreciation of $46,138,000. At December 31, 2013, the Company held equipment under operating lease contracts with customers with an original cost of $86,712,000 and accumulated depreciation of $43,805,000.
	Certificate of deposit – As of December 31, 2014 and 2013, the Company had a $9,000,000 investment in a certificate of deposit with a bank. On January 2, 2015 proceeds from the certificate of deposit were used to pay-off the Company’s line of credit agreement with the same bank who issued the certificate of deposit.
	Investment in equity securities – As of December 31, 2014 the Company had common stock representing an approximate 0.77% interest in Mevion Medical Systems, Inc. (“Mevion”), and accounts for this investment under the cost method. The cost of the Company’s investment in Mevion was $2,709,000 and $2,701,000 as of December 31, 2014 and December 31, 2013, respectively. The Company reviews its investment in Mevion for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. See Note 4 – Investment in Equity Securities for further discussion.
	Fair value of financial instruments – The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.
	The estimated fair value of the Company’s assets and liabilities as of December 31, 2014 and December 31, 2013 were as follows (in thousands):
												Carrying
		Level 1			Level 2			Level 3		Total		Value
	31-Dec-14
	Assets:
	Cash, cash equivalents, restricted cash	$	1,109		$	-		$	-	$	1,109	$	1,109
	Certificate of deposit		9,000			-					9,000		9,000
	Investment in equity securities		-			-			330		330		2,709
	Total	$	10,109		$	-		$	330	$	10,439	$	12,818
	Liabilities
	Advances on line of credit		8,780			-			-		8,780		8,780
	Debt obligations		-			10,658			-		10,658		10,591
	Total	$	8,780		$	10,658		$	-	$	19,438	$	19,371
	31-Dec-13
	Assets:
	Cash, cash equivalents, restricted cash	$	1,959		$	-		$	-	$	1,959	$	1,959
	Certificate of deposit		9,000			-			-		9,000		9,000
	Investment in equity securities		-			-			300		300		2,701
	Total	$	10,959		$	-		$	300	$	11,259	$	13,660
	Liabilities
	Advances on line of credit		8,840			-			-		8,840		8,840
	Debt obligations		-			15,082			-		15,082		15,544
	Total	$	8,840		$	15,082		$	-	$	23,922	$	24,384
	Revenue recognition - Revenue is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. As of December 31, 2014, there are no guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing.
	Revenue from fee per use contracts is determined by each hospital’s contracted rate. Revenue is recognized at the time the procedures are performed, based on each hospital’s contracted rate. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the Gamma Knife. The Company also records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The gross amount the Company expects to receive is recorded as revenue and estimated based on historical experience and hospital contracts with third party payors. Revenue estimates are reviewed periodically and adjusted as necessary. Revenue recognition is consistent with guidelines provided under the applicable accounting standards for revenue recognition.
	Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 9 for additional information on the Company’s stock-based compensation programs.
	Costs of revenue – The Company's costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites). Costs of revenues are recognized as incurred.
	Sales and Marketing – The Company markets its services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development and its Chief Operating Officer. The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services. The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services.
	Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. See Note 8 for further discussion on income taxes.
	Comprehensive income (loss) – Comprehensive income (loss) encompasses all changes in shareholders’ equity other than those arising from transactions with stockholders, and consists of net loss and foreign currency translation adjustments.
	Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are initially accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will change its accounting for the operation to the local currency from the U.S. dollar.
	The Company determined that the functional currency of its Turkish operation, EWRS Turkey, should change from the U.S. dollar to the Turkish lira effective in the third quarter 2012. Therefore, in accordance with ASC 830, EWRS Turkey’s balance sheet accounts were translated at rates in effect as of August 31, 2012, or other rates in accordance with guidance provided under ASC 830, and accumulated gains and losses and translation differences were recorded in accumulated other comprehensive loss, which is a separate component of shareholders’ equity. Monthly, the Company's balance sheet accounts were translated at rates in effect as of the balance sheet date, and income and expense accounts were translated at the weighted average rates of exchange during the period following the change. Translation adjustments resulting from this process were also recognized under accumulated other comprehensive loss.
	Gains and losses from foreign currency transactions and remeasurement are listed in the Company’s consolidated statements of operations. The net foreign currency gain for 2014, prior to the sale of EWRS Turkey, was $161,000 compared to a loss in 2013 of $1,174,000, and a gain of $132,000 in 2012.
	Cumulative translation adjustment – Based on guidance provided in accordance with ASU No 2013-05 Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries of Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (“ASU 2013-05”), the Company no longer holds a financial interest in EWRS Turkey. As such, the cumulative translation adjustments previously recognized under accumulated other comprehensive income (loss) were released into net income as a component of the loss for the sale of EWRS Turkey in the statement of operations. The total cumulative translation adjustment of $779,000, previously recognized under accumulated other comprehensive income (loss), was included as a component of the loss calculation for the sale of EWRS Turkey, reported in the statement of operations for the year ended 2014.
	Discontinued Operations – Based on guidance provided in accordance with ASU No. 2014-08 Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), the Company has analyzed the factors that define a discontinued operation and determined that the sale of EWRS Turkey is considered the sale of a significant component, but does not represent a major shift in the business, and therefore is not a discontinued operation.
	Effective May 31, 2014 (with closing occurring June 10, 2014) the Company sold EWRS Turkey for EUR 4.2 million (approximately $6.0M). The proceeds were used to reduce outstanding debt and the excess was cash to the Company of $768,000. Cash transactions were recorded for the time period June 1 to June 10, 2014, the date of closing. The Company recorded a loss on sale of subsidiary of $572,000. The Company is also eligible for an earn-out in fiscal years 2014 and 2015 based on future revenue derived from the units sold to Euromedic. It is not practicable to estimate the revenue from the earn-outs at this time and therefore no amounts have been recorded as of December 31, 2014
	Earnings per share – Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options or warrants. The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2014, 2013 and 2012.
		2014			2013			2012
	Numerator for basic and diluted (loss) earnings per share	$	-952,000		$	-312,000		$	38,000
	Denominator:
	Denominator for basic (loss) earnings per share – weighted-average shares		5,028,000			4,608,000			4,609,000
	Effect of dilutive securities
	Employee stock options/restricted stock units		3,000			3,000			3,000
	Denominator for diluted (loss) earnings per share – adjusted weighted- average shares		5,031,000			4,611,000			4,612,000
	(Loss) earnings per common share- basic	$	-0.19		$	-0.07		$	0.01
	(Loss) earnings per common share- diluted	$	-0.19		$	-0.07		$	0.01
	In 2014, options outstanding to purchase 633,000 shares of common stock at an exercise price range of $2.43 - $6.16 per share, and warrants to purchase 200,000 sharesof common stock, issued with promissory notes, at an exercise price of $2.20, were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
	In 2013, options outstanding to purchase 576,000 shares of common stock at an exercise price range of $2.30 - $6.50 per share were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
	In 2012, options outstanding to purchase 588,000 shares of common stock at an exercise price range of $2.76 - $6.50 per share were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
	Business segment information - The Company, which engages in the business of leasing radiosurgery and radiation therapy equipment to health care providers, has one reportable segment, Medical Services Revenue.
The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment:
	2014		2013		2012
Medical services revenues
Domestic	97	%	91	%	93	%
Foreign	3	%	9	%	7	%
Total	100	%	100	%	100	%
	2014		2013
Property and equipment, net
Domestic	94	%	84	%
Foreign	6	%	16	%
Total	100	%	100	%
Nonmonetary transactions – Based on guidance provided in accordance with ASC No. 845 Nonmonetary Transactions (“ASC 845”), barter transactions with commercial substance are recorded at the estimated fair value of the products exchanged, unless the products received have a more readily determinable estimated fair value. The Company entered into a lease agreement in December 2014 where the lessee exchanged certain medical services equipment for a nominal amount and more beneficial contract terms related to the revenue sharing arrangement. The Company estimated and recorded the fair value of the equipment received and recognized deferred revenue. The fair value of the equipment received during the year ended December 31, 2014 was $700,000.
Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to operations in the period in which management determines such impairment. No such impairment has been noted as of December 31, 2014 and 2013.
Out-of-Period Adjustment: During the fourth quarter of 2014, the Company reclassified $400,000 to non-controlling interests and $235,000 to additional paid-in capital that were incorrectly classified as liabilities. The corrections were not material to any previously reported financial periods or to the year ended December 31, 2014.
Recently issued accounting pronouncements – In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASU 2014-09"), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern ("ASU 2014-15 "). ASU 2014-15 provides guidance in GAAP about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for reporting periods ending after December 15, 2016. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to affect the Company's consolidated financial position, results of operations or cash flows.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 3 – Property and Equipment
	Property and equipment consists of the following:
		DECEMBER 31,
		2014		2013
	Medical equipment and facilities	$	82,151,000	$	86,712,000
	Office equipment		721,000		749,000
	Deposits and construction in progress		8,736,000		4,719,000
	Deposits towards purchase of proton beam systems		5,000,000		3,000,000
			96,608,000		95,180,000
	Accumulated depreciation		-46,572,000		-43,799,000
	Net property and equipment	$	50,036,000	$	51,381,000
	The Company has equipment that is secured under capitalized leases, which is included in Medical equipment and facilities, with a total cost of $29,548,000 and associated accumulated depreciation of $11,269,000 as of December 31, 2014 and a total cost of $30,538,000 and associated accumulated depreciation of $9,858,000 as of December 31, 2013.
	As of December 31, 2014, the Company has $5,000,000 in deposits toward the purchase of three MEVION S250 proton beam radiation therapy (“PBRT”) systems from Mevion. The Company has a commitment for the remaining balance for each system. The Company’s first PBRT system was delivered in 2014. The Company has entered into a partnership agreement (LBE) with a radiation oncology physician group, which has contributed $400,000 towards the deposits on the third machine. The Company reviews the carrying value of these deposits for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value may not be recoverable. See Note 12-Commitments and Contingencies for additional discussion on purchase commitments.

INVESTMENT_IN_EQUITY_SECURITIE

INVESTMENT IN EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2014
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Note 4 – Investment in Equity Securities
	On April 10, 2006 the Company invested $2,000,000 for a convertible preferred stock interest in Mevion, formerly Still River Systems, Inc., a development-stage company based in Littleton, Massachusetts, which in collaboration with scientists from MIT’s Plasma Science and Fusion Center, is developing a medical device for the treatment of cancer patients using proton beam radiation therapy. The Company also has deposits towards the purchase of three Mevion PBRT systems as described more fully in Note 3.
	The Company’s initial investment in Mevion consisted of approximately 2,353,000 shares of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock is considered pari passu with previously issued Series A Convertible Preferred Stock.
	On September 5, 2007 the Company invested approximately $617,000 for an additional equity interest in Mevion. This investment represented approximately 588,000 shares of Series C Convertible Preferred Stock, which is considered pari passu with the previously issued Series A and Series B Convertible Preferred Stock (all issues together “Preferred Stock”).
	Since October 2008 Mevion had continued to offer a sequence of Series D rounds of funding to raise cash for its next phase of development and continued manufacture of the prototype model of the proton beam unit. Due to the troubled economy and scarcity of funds available during this time, these rounds were offered at a price less than the Company’s investment. Mevion received approximately $65 million from these Series D rounds.
	In mid-2011, Mevion performed a reverse stock split of all shares in which 100 shares were converted to one share. The reason for the reverse stock split was to move the number of outstanding shares and price per share more in line with industry norms. The reverse stock split did not change any investor’s relative ownership in Mevion.
	In January 2012, Mevion announced that it had closed a $45 million Series E round of financing which was used to accelerate the manufacturing and worldwide deployment of the MEVION S250. This round of financing was offered at a price per share higher than the effective price of the most recent Series D financing, and initially funded at 55%, with the remaining 45% due upon Mevion’s receipt of final FDA 510(k) clearance, which occurred during the second quarter 2012. The Company invested an additional $70,000 in the Series E round.
	In June 2013, Mevion announced that it had secured a $55 million Series E round of financing, which will be used to accelerate the manufacturing and worldwide deployment of the MEVION S250. This round of financing was offered at a price per share higher than the effective price of the most recent Series E financing. The Company did not participate in this round of funding. Subject to the Pay-to-Play Provision, implemented through the amendment of the Sixth Amended and Restated Articles of Incorporation, the preferred shares held by the Company were converted to common shares.
	Upon conversion of the Preferred Stock, the Company’s investment represents an approximate 0.77% interest in the common stock of Mevion where it remained as of December 31, 2014. The Company does not have a Board of Directors seat with Mevion.
	In December 2014 Mevion announced that it had secured a $10M round of financing, which will be used to accelerate the manufacturing and worldwide deployment of the MEVION S250. This round of financing was offered at a price per share higher than the effective price of the most recent Series E financing. The Company did not participate in this round of funding.
	The Company accounts for its investment in Mevion under the cost method and evaluates the investment for impairment on a quarterly basis or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. The Company reviewed its investment in Mevion at December 31, 2014 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room PBRT system.
	The lower price per share of the Series D and Series E offerings could be viewed as a reasonable estimate of the fair value of our cost-method investment, indicating that our investment is impaired. The Company estimates that there is currently an unrealized loss (impairment) of approximately $2.4M based on the issuance of the Series E funding compared to the Company’s cost of its investment.
	In assessing whether the impairment is other than temporary, we evaluated the length of time and extent to which market value has been below cost, the financial condition and near term prospects of Mevion and our ability and intent to retain our investment for a period sufficient to allow for an anticipated recovery in the market value. Although the investment is not without certain risk, and the manufacture of the first unit has taken longer than originally anticipated, the Company believes that the current market value is a temporary situation and that the successful operation of the first MEVION S250 System and Mevion’s significant revenue backlog provide a higher potential valuation.

LONGTERM_DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Note 5 – Long-Term Debt
	Long-term debt consists primarily of eight notes with financing companies, related to Gamma Knife equipment and construction and installation, totaling $9,724,000, as of December 31, 2014. These notes are payable in 36 to 84 fully amortizing monthly installments, mature between December 2015 and November 2021, and are collateralized by the respective Gamma Knife units. The notes accrue interest at fixed annual rates between 3.95% and 7.48%. Long term debt as of December 31, 2014 also includes $1,000,000 in promissory notes and warrants funded by four members of the Company’s Board of Directors. The fair value of the warrants are estimated at $145,000 and are reported as capital contributed during 2014. The promissory notes are reported net of the amount allocated to the warrants, which is amortized over the term of the obligation. See Note 13-Note, Warrant, & Common Stock Purchase Agreement for additional discussion on promissory notes and warrants with the Board. As of December 31, 2013 long-term debt consisted of eleven notes totaling $15,544,000.
	The following are contractual maturities of long-term debt by year at December 31, 2014:
	Year ending December 31,	Principal		Interest
	2015	$	2,053,000	$	654,000
	2016		2,698,000		525,000
	2017		2,669,000		369,000
	2018		1,546,000		159,000
	2019		891,000		85,000
	Thereafter		867,000		58,000
		$	10,724,000	$	1,850,000

OBLIGATIONS_UNDER_CAPITAL_LEAS

OBLIGATIONS UNDER CAPITAL LEASES	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt and Capital Leases Disclosures [Text Block]	Note 6 – Obligations Under Capital Leases
	The Company has ten capital lease obligations with four financing companies, collateralized by Gamma Knife equipment having an aggregate net book value of $18,279,000 at December 31, 2014. These obligations have stated interest rates ranging between 5.15% and 9.50%, are payable in 60 to 84 monthly installments, and mature between July 2015 and May 2020. As of December 31, 2013, the Company had nine capital lease obligations with four finance companies with an aggregate net book value of $20,680,000. At the end of the lease term, the Company has a bargain purchase option to purchase the equipment.
	Future minimum lease payments, together with the present value of the net minimum lease payments under capital leases at December 31, 2014, are summarized as follows:
		Net Present Value
		of Minimum
		Lease Payments
	Year ending December 31,
	2015	$	5,108,000
	2016		4,783,000
	2017		4,282,000
	2018		2,714,000
	2019		1,415,000
	Thereafter		380,000
	Total capital lease payments		18,682,000
	Less imputed interest		2,389,000
			16,293,000
	Less current portion		4,103,000
		$	12,190,000

LINE_OF_CREDIT

LINE OF CREDIT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 – Line of Credit
	As of December 31, 2014 and 2013, the Company had a $9,000,000 renewable line of credit with a bank secured by a certificate of deposit. The line of credit has been in place since June 2004. The Company’s earnings in 2013 were insufficient to satisfy the “profitability” covenant in the line of credit. The Bank waived this default on August 8, 2014 and agreed to change the maturity date of the facility to December 31, 2014. The line was paid-off using the proceeds from the certificate of deposit on January 2, 2015.
	Borrowing under the line of credit is subject to interest expense at a rate equal to the bank’s prime rate minus 0.5 percentage point, or alternatively at the Company’s discretion, the LIBOR rate plus 1.0 percentage point. The weighted average interest rate on money borrowed against the line of credit during 2014 was 1.40%. As of December 31, 2014 and 2013, there was $8,780,000 and $8,840,000 borrowed against the line of credit, respectively.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 8 – Income Taxes
	The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made no reclassifications between current taxes payable and long term taxes payable under this guidance. Also, the Company had no amounts of unrecognized tax benefits that, if recognized, would affect its effective income tax rate for the years ended December 31, 2014, 2013 and 2012.
	The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as taxes. As of December 31, 2014, the Company had no amount accrued for the payment of interest and penalties related to unrecognized tax benefits.
	The tax return years 2010 through 2014 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Additionally, net operating losses generated on a tax return basis by the Company for calendar years 1999 through 2004 and 2009 remain open to examination by the major domestic taxing jurisdictions.
	Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2014 and 2013 are as follows:
		DECEMBER 31,
		2014		2013
	Deferred tax liabilities:
	Property and equipment	$	-7,145,000	$	-7,201,000
	Total deferred tax liabilities		-7,145,000		-7,201,000
	Deferred tax assets:
	Net operating loss carryforwards		3,424,000		3,607,000
	Accruals and allowances		173,000		240,000
	Tax credits		319,000		318,000
	Other – net		235,000		101,000
	Capital loss carryover		437,000		-
	Total deferred tax assets		4,588,000		4,266,000
	Valuation allowance		-549,000		-95,000
	Deferred tax assets net of valuation allowance		4,039,000		4,171,000
	Net deferred tax liabilities	$	-3,106,000	$	-3,030,000
	These amounts are presented in the financial statements as follows:
		DECEMBER 31,
		2014		2013
	Current deferred tax assets	$	367,000	$	342,000
	Deferred income taxes (non-current)		-3,473,000		-3,372,000
		$	-3,106,000	$	-3,030,000
	The components of the provision for income taxes consist of the following:
		YEARS ENDED DECEMBER 31,
			2014		2013		2012
	Current:
	Federal	$	-	$	-	$	18,000
	State		54,000		23,000		65,000
	Foreign		-		-		-
	Total current		54,000		23,000		83,000
	Deferred:
	Federal		-131,000		184,000		95,000
	State		40,000		12,000		-41,000
	Foreign		166,000		-135,000		-30,000
	Total deferred		75,000		61,000		24,000
		$	129,000	$	84,000	$	107,000
	The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (34% in 2014, 2013 and 2012) to income before taxes as follows:
		YEARS ENDED DECEMBER 31,
		2014		2013		2012
	Computed expected federal income tax	$	-280,000	$	-92,000	$	49,000
	State income taxes, net of federal benefit		66,000		120,000		38,000
	Non-deductible expenses		21,000		28,000		24,000
	Change in valuation allowance		416,000		-68,000		-61,000
	Other		-94,000		96,000		57,000
		$	129,000	$	84,000	$	107,000
	At December 31, 2014, the Company had net operating loss carryforwards for federal income tax return purposes of approximately $9,518,000 which expire between 2019 and 2033. The Company has net operating loss carryforwards for state income tax purposes of approximately $1,540,000 that begin to expire in 2014 and 2029. A substantial part of this carryforward is subject to separate return limitations.
	Due to uncertainty surrounding the realization of capital losses and certain state net operating losses, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance increased by $416,000, decreased by $68,000, and decreased by $61,000 for the tax years ended December 31, 2014, 2013, and 2012, respectively.
	The Company’s ability to utilize its net operating loss carryforwards and other deferred tax assets may be limited in the event of a 50% or more ownership change within any three-year period. Future federal net operating losses generated by the Company can be carried forward for 20 years.
	It is the intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. income taxes on the earnings of foreign subsidiaries as such earnings are to be reinvested indefinitely. As of December 31, 2014, there is a minimal cumulative amount of earnings upon which U.S. income taxes have not been provided.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Shareholders’ Equity
	Incentive Compensation Plan
	In June 2010 shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000. The Plan provides that the shares reserved under the Plan are available for issuance to officers of the Company, other key employees, non-employee directors, and advisors. The Plan is a successor to the Company’s previous plans, and any shares awarded and outstanding under those plans were transferred to the Plan. No further grants or share issuances will be made under the previous plans. As of December 31, 2014, approximately 738,000 shares remain available for grant under the Plan.
	The Plan provides for nonqualified stock options, qualified (or incentive) stock options and stock grants. The Plan has a provision to reduce the number of shares reserved for award and issuance under the Plan by a ratio of 1.59 shares of common stock for each share of common stock that is issued pursuant to a Full Value Award (stock grant).
	The Plan also provides for an Incentive Bonus Program with incentive bonus opportunities through performance unit awards and special cash incentive programs tied to the attainment of pre-established performance milestones.
	Provisions of the Plan include an automatic annual grant to each non-employee director of options to purchase up to 2,000 shares on the date of the Company’s Annual Shareholder Meeting, at an exercise price equal to the market price of the Company’s common shares on that date, an automatic annual grant of 500 restricted stock units of the Company’s common shares and an annual cash retainer fee for Board or Board Committee service, which may be converted to restricted stock unit awards. Options and restricted stock units awarded under the automatic annual grant program for non-employee directors vest after one year. Restricted stock units awarded in lieu of retainer fees vest quarterly, over a one year period. These awards become outstanding upon the conclusion of the individual Board members service on the Company’s Board of Directors. Other options may vest fully and immediately, or over periods of time as determined by the Plan Administrator, but no longer than seven years from the grant date. Discretionary options currently awarded under the Plan vest over a period of 5 years.
	Under the Plan, a total of 138,000 restricted stock units have been granted, consisting of 23,000 of annual automatic grants to non-employee directors and the corporate secretary and 115,000 of deferred retainer fees to non-employee members of the Board. The restricted stock units are fully vested but not yet deemed issued and outstanding as of December 31, 2014. The Company granted 3,000 shares of restricted stock and 30,000 shares of restricted stock in lieu of retainer fees in 2014 with a fair value of $2.64 per share. For the year ended December 31, 2014, total compensation expense recorded in the consolidated statements of income related to restricted stock units in lieu of retainer fees was $80,000. For the year ended December 31, 2014, total compensation expense recorded in the consolidated statements of income for annual restricted stock units awarded was $7,000, with an offsetting tax benefit of $1,900, as this expense is deductible for income tax purposes. As of December 31, 2014, there was $2,100 of total unrecognized compensation cost related to annual restricted sock units which is expected to be recognized over a period of .5 years. During 2014, 2013, and 2012 shares of restricted stock units totaling 3,000 with a fair value of approximately $6,000 vested and became unrestricted.
	Changes in stock options outstanding under the Incentive Compensation Plans during 2014 are as follows :
							Weighted
				Weighted			Average
				Average			Remaining	Aggregate
		Number		Exercise			Contractual	Intrinsic
	Options	of Options		Price			Term (Years)	Value
	Balance at December 31, 2013	601,000		$	3.5
	Granted	522,000		$	2.89
	Exercised	-		$	-
	Forfeited	-464,000		$	3.34
	Balance at December 31, 2014	659,000		$	3.13		5.57	$	-
	Exercisable at December 31, 2014	123,000		$	4.25		2.15	$	-
	The weighted average grant-date fair value of the options granted during the years 2014, 2013 and 2012 was $1.23, $1.28, and $1.60 respectively. There was no total intrinsic value of options exercised during any of the years ended December 31, 2014 and 2013 and 2012.
	There was no cash received from options exercised under any share-based payment arrangements for the years ended December 31, 2014, 2013 and 2012, and as a result, there was no actual tax benefit realized for tax deductions from option exercises in any of those years.
	Total compensation expense recognized for stock options for the years ended December 2014, 2013, and 2012 was $51,000, $88,000, and $74,000, respectively.
	A summary of the status of the Company’s non-vested shares as of December 31, 2014, and changes during the year ended December 31, 2014 is presented below:
				Weighted
				Average
		Number		Grant-Date
	Nonvested Shares	of Options		Fair Value
	Nonvested at December 31, 2013	26,000		$	1.25
	Granted	522,000		$	1.23
	Vested	-12,000		$	1.14
	Forfeited	-		$	-
	Nonvested at December 31, 2014	536,000		$	1.23
	At December 31, 2014, there was approximately $732,000 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. This cost is expected to be recognized over a period of approximately five years.
	The Company’s stock-based awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards to employees.
	The fair value of the Company’s option grants issued during 2014, 2013 and 2012 were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period.
	The fair value of the Company’s option grants under the Plan in 2014, 2013 and 2012 was estimated using the following assumptions:
		2014		2013		2012
	Expected life (years)	7		7		7
	Expected forfeiture rate	0	%	0	%	0.0 -  4.0	%
	Expected volatility	40	%	49	%	40 - 45	%
	Dividend yield	0	%	0	%	0	%
	Risk-free interest rate	2	%	2.6 - 3.0	%	1.7	%
	Repurchase of Common Stock, Common Stock Warrants and Stock Options
	In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. During 2014, the Company repurchased approximately 1,000 shares of its stock on the open market. There were no shares of the Company repurchased during 2013. During 2012 the Company repurchased approximately 9,000 shares of its stock on the open market. There are approximately 72,000 shares remaining under this repurchase authorization.

RETIREMENT_PLAN

RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 10 – Retirement Plan
	The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For 2014, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4% of the participant’s annual compensation. Discretionary profit sharing contributions are allowed under the Retirement Plan in years that the Board does not elect a safe harbor match. The Company has accrued approximately $43,000 for the estimated safe harbor matching contribution for the year ended December 31, 2014. The Company contributed $41,000 to the Retirement Plan for the safe harbor match for the years ended December 31, 2013 and December 31, 2012, respectively.

OPERATING_LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Operating Leases of Lessor Disclosure [Text Block]	Note 11 – Operating Leases
	The Company leases office space and equipment under operating leases expiring at various dates through 2016. Future minimum payments under non-cancelable operating leases, net of expected sublease income, having initial terms of more than one year consisted of the following:
	Year ending December 31,
	2015	$	114,000
	2016		61,000
	Thereafter		-
		$	175,000
	Payments for repair and maintenance agreements incorporated in operating lease agreements are not included in the future minimum operating lease payments shown above.
	Net rent expense was $301,000, $549,000, and $438,000 for the years ended December 31, 2014, 2013 and 2012, respectively, and includes the above operating leases as well as month-to-month rental and certain executory costs. Total rent expense was recognized net of sublease income of $173,000 and $116,000 for the years ended December 31, 2014 and 2013. In 2013, the Company subleased a portion of its existing office space through the remainder of its lease term at a rate lower than its lease rate, resulting in a cumulative loss of $115,000. This loss will be amortized against total rent expense over the term of the sublease and it is included in total rent expense for 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 – Commitments and Contingencies
	As of December 31, 2014, the Company has contractual commitments to purchase three PBRT systems, one Gamma Knife Perfexion system, one Gamma Knife model 4C system, and two Cobalt-60 reloads, both at existing sites. Financing has been committed to the Model 4C unit and the Cobalt-60 reloads at existing sites. The Company has a lease financing commitment, pending execution of definitive documents, for an additional $9,000,000, for its first PBRT project. The total of these commitments is approximately  $45,434,000, of which, the Company has made non-refundable deposits totaling approximately $7,784,000 towards the purchase of this equipment. The timing of progress payments for PBRT contracts two and three are dependent upon future events, for which, the Company has some latitude in the timing of the due dates of these commitments. Approximately $27,000,000 of these commitments are not expected to start becoming due until 2016.
		Commitment		Cash Deposits
	Proton Beam Units	$	38,600,000	$	5,000,000
	Gamma Knife Units		6,834,000		2,784,000
	Total Commitments	$	45,434,000	$	7,784,000
	The Gamma Knife model 4C system is projected to be installed in late 2015 at the Company’s new customer site in Peru. The Perfexion is for a site yet to be determined. The first PBRT system was delivered in December 2014 and the remaining two currently have anticipated delivery dates in 2015 and later, pending certain construction milestones. The deposits and progress payments are classified as deposits and construction in progress under Property and Equipment.

NOTE_WARRANT_COMMON_STOCK_PURC

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2014
Note, Warrant And Common Stock Purchase Agreement [Abstract]
Note, Warrant And Common Stock Purchase Agreement [Text Block]	Note 13 – Note, Warrant, & Common Stock Purchase Agreement
	The Company entered into a common stock purchase agreement (the “Purchase Agreement”) with three members of the Company’s Board of Directors, to sell, in a private offering, an aggregate of 650,000 shares of the Company’s common stock, no par value, for gross proceeds of approximately $1,600,000. The private offering closed on June 12, 2014. The Shares are restricted securities and may not be offered or sold absent registration under the Securities
	Act of 1933. Pursuant to the terms of the Purchase Agreement, the Company has agreed to provide demand registration rights with respect to the Shares, with certain limited exceptions. The Investors’ demand registration rights will expire on June 12, 2015. Pursuant to the terms of the Purchase Agreement, the Company has also granted the Investors a one-year preemptive right to participate pro rata in future issuances of the Company’s common stock.
	The Company entered into a Note and Warrant Purchase Agreement (the “Note and Warrant Purchase Agreement”) with four members of the Company’s Board of Directors to issue an aggregate of $1,000,000 in principal amount of promissory notes (the “Notes”) and warrants (the “Warrants”) to purchase an aggregate of 200,000 shares of the common stock, no par value (the “Common Stock”), of the Company (the “Notes and Warrants Offering”). The Notes will bear interest at a rate of 15.0% per annum and mature October 22, 2017. Interest only payments are due monthly with the option to prepay the outstanding principal on or after December 31, 2015. The Company is required to prepay the outstanding principal within five days of the next milestone payment to Mevion, if that occurs before the maturity date. The Warrants expire three years after their initial issuance date and may be exercised for a purchase price equal to $2.20 per share of Common Stock, the closing price per share of the Company’s Common Stock on the New York Stock Exchange MKT on the date preceding the date of the Note and Warrant Purchase Agreement.
	Concurrently with the Note and Warrant Purchase Agreement, the Company entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) with one member of the Company’s board of directors to sell, in a private offering, 100,000 shares of the Company’s Common Stock (the “Private Placement Shares”), for gross proceeds of $220,000 (the “Common Stock Offering” and, together with the Notes and Warrants Offering, the “Private Offering”). The Common Stock Purchase Agreement contains terms and conditions that are customary for a transaction of this type.
	The Company received gross proceeds of $1,220,000 in the Private Offering, which were used, together with cash on hand, to make two payments of $1,000,000 each to Mevion as deposits pursuant to the terms of purchase commitments with Mevion.

SIGNIFICANT_RELATED_PARTY_TRAN

SIGNIFICANT RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 14 – Significant Related Party Transactions
	The Company’s Gamma Knife and IGRT businesses in Turkey was operated through EWRS Turkey. GKF owned indirectly 70% of EWRS Turkey, through its 70% ownership of EWRS LLC. The remaining 30% ownership of EWRS LLC was held by EMKA LLC (“EMKA”). EMKA is owned and operated by Mert Ozyurek (“Mr. Ozyurek”) who also sits on the Board of Directors of the Company. Mr. Ozyurek operates a foreign company called Ozyurek A.S. EWRS Turkey purchased its two Gamma Knife units from Ozyurek A.S. and had contracts for service and maintenance on the machines. The Company believes all its transactions with Mr. Ozyurek were arm’s-length transactions.
	The Company’s Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its units from Elekta, there are significant related party transactions with Elekta such as equipment purchases, commitments to purchase equipment, deposits for such equipment purchases, and costs to maintain the equipment. The Company believes that all its transactions with Elekta are arm’s-length transactions. At December 31, 2014, the Company had commitments to purchase one Gamma Knife Perfexion system, one Gamma Knife model 4C system and two Cobalt-60 reloads from Elekta, as discussed in Note 12.

MAJOR_CUSTOMERS

MAJOR CUSTOMERS	12 Months Ended
	Dec. 31, 2014
Major Customers [Abstract]
Major Customers [Text Block]	Note 15 – Major Customers
	The Company’s revenue was provided by twenty customers in 2014 and nineteen customers in 2013 and 2012. In 2014, two customers each accounted for approximately 9% of total revenue. In 2013, two customers each accounted for approximately 10% of total revenue. In 2012, two customers accounted for approximately 13% and 11% of total revenue.

SUBSESQUENT_EVENTS

SUBSESQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 16 – Subsequent Events
	The Company has evaluated subsequent events through the date the financial statements were available to be issued.

ACCOUNTING_POLICIES_Policies

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates in the preparation of financial statements – In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include the allowance for doubtful accounts, estimated useful lives of fixed assets and its salvage values, revenues and costs of sales for turn-key and revenue sharing arrangements, and the carrying value of its Mevion investment.  Actual results could differ from those estimates.
Advertising Costs, Policy [Policy Text Block]	Advertising costs – The Company expenses advertising costs as incurred. Advertising costs were $155,000, $119,000, and $103,000 during the years ended December 31, 2014, 2013, and 2012, respectively. Advertising costs are recorded in other direct operating costs and sales and administrative costs in the consolidated statements of operations
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations.
Business Combinations And Credit Risk [Policy Text Block]	Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. Currently much of the Company’s cash is invested in a certificate of deposit. The Company has not experienced any losses and believes it is not exposed to any significant credit risk on cash, cash equivalents and securities. The Company monitors the financial condition of the financial institutions it uses on a regular basis.
	All of the Company’s revenue was provided by twenty and nineteen customers in 2014 and 2013, and these customers constitute accounts receivable at December 31, 2014 and 2013, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts receivable and doubtful accounts – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for probable losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are recorded as revenue when received.
Non-controlling Interests [Policy Text Block]	Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. The Company also presents the consolidated net income and the portion of the consolidated net income and other comprehensive income allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations and comprehensive income (loss).
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 – 15 years, and after accounting for salvage value on the equipment where indicated. Salvage value is based on the estimated fair value of the equipment at the end of its useful life. The Company capitalized interest of $371,000, $390,000, and $196,000 in 2014, 2013, and 2012, respectively, as costs of medical equipment.
	The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2014, the Company held equipment under operating lease contracts with customers with an original cost of $82,151,000 and accumulated depreciation of $46,138,000. At December 31, 2013, the Company held equipment under operating lease contracts with customers with an original cost of $86,712,000 and accumulated depreciation of $43,805,000
Certificate Of Deposit [Policy Text Block]	Certificate of deposit – As of December 31, 2014 and 2013, the Company had a $9,000,000 investment in a certificate of deposit with a bank. On January 2, 2015 proceeds from the certificate of deposit were used to pay-off the Company’s line of credit agreement with the same bank who issued the certificate of deposit.
Investment, Policy [Policy Text Block]	Investment in equity securities – As of December 31, 2014 the Company had common stock representing an approximate 0.77% interest in Mevion Medical Systems, Inc. (“Mevion”), and accounts for this investment under the cost method. The cost of the Company’s investment in Mevion was $2,709,000 and $2,701,000 as of December 31, 2014 and December 31, 2013, respectively. The Company reviews its investment in Mevion for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. See Note 4 – Investment in Equity Securities for further discussion.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments – The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.
	The estimated fair value of the Company’s assets and liabilities as of December 31, 2014 and December 31, 2013 were as follows (in thousands):
												Carrying
		Level 1			Level 2			Level 3		Total		Value
	31-Dec-14
	Assets:
	Cash, cash equivalents, restricted cash	$	1,109		$	-		$	-	$	1,109	$	1,109
	Certificate of deposit		9,000			-					9,000		9,000
	Investment in equity securities		-			-			330		330		2,709
	Total	$	10,109		$	-		$	330	$	10,439	$	12,818
	Liabilities
	Advances on line of credit		8,780			-			-		8,780		8,780
	Debt obligations		-			10,658			-		10,658		10,591
	Total	$	8,780		$	10,658		$	-	$	19,438	$	19,371
	31-Dec-13
	Assets:
	Cash, cash equivalents, restricted cash	$	1,959		$	-		$	-	$	1,959	$	1,959
	Certificate of deposit		9,000			-			-		9,000		9,000
	Investment in equity securities		-			-			300		300		2,701
	Total	$	10,959		$	-		$	300	$	11,259	$	13,660
	Liabilities
	Advances on line of credit		8,840			-			-		8,840		8,840
	Debt obligations		-			15,082			-		15,082		15,544
	Total	$	8,840		$	15,082		$	-	$	23,922	$	24,384
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition - Revenue is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. As of December 31, 2014, there are no guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing.
	Revenue from fee per use contracts is determined by each hospital’s contracted rate. Revenue is recognized at the time the procedures are performed, based on each hospital’s contracted rate. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the Gamma Knife. The Company also records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The gross amount the Company expects to receive is recorded as revenue and estimated based on historical experience and hospital contracts with third party payors. Revenue estimates are reviewed periodically and adjusted as necessary. Revenue recognition is consistent with guidelines provided under the applicable accounting standards for revenue recognition.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 9 for additional information on the Company’s stock-based compensation programs.
Cost of Sales, Policy [Policy Text Block]	Costs of revenue – The Company's costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites). Costs of revenues are recognized as incurred.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Sales and Marketing – The Company markets its services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development and its Chief Operating Officer. The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services. The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services.
Income Tax, Policy [Policy Text Block]	Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. See Note 8 for further discussion on income taxes.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income (loss) – Comprehensive income (loss) encompasses all changes in shareholders’ equity other than those arising from transactions with stockholders, and consists of net loss and foreign currency translation adjustments.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters (“ASC 830”), the Company analyzes its operations outside the United States to determine the functional currency of each operation. Management has determined that these operations are initially accounted for in U.S. dollars since the primary transactions incurred are in U.S. dollars and the Company provides significant funding towards the startup of the operation. When Management determines that an operation has become predominantly self-sufficient, the Company will change its accounting for the operation to the local currency from the U.S. dollar.
	The Company determined that the functional currency of its Turkish operation, EWRS Turkey, should change from the U.S. dollar to the Turkish lira effective in the third quarter 2012. Therefore, in accordance with ASC 830, EWRS Turkey’s balance sheet accounts were translated at rates in effect as of August 31, 2012, or other rates in accordance with guidance provided under ASC 830, and accumulated gains and losses and translation differences were recorded in accumulated other comprehensive loss, which is a separate component of shareholders’ equity. Monthly, the Company's balance sheet accounts were translated at rates in effect as of the balance sheet date, and income and expense accounts were translated at the weighted average rates of exchange during the period following the change. Translation adjustments resulting from this process were also recognized under accumulated other comprehensive loss.
	Gains and losses from foreign currency transactions and remeasurement are listed in the Company’s consolidated statements of operations. The net foreign currency gain for 2014, prior to the sale of EWRS Turkey, was $161,000 compared to a loss in 2013 of $1,174,000, and a gain of $132,000 in 2012.
Cumulative Translation Adjustment [Policy Text Block]	Cumulative translation adjustment – Based on guidance provided in accordance with ASU No 2013-05 Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries of Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (“ASU 2013-05”), the Company no longer holds a financial interest in EWRS Turkey. As such, the cumulative translation adjustments previously recognized under accumulated other comprehensive income (loss) were released into net income as a component of the loss for the sale of EWRS Turkey in the statement of operations. The total cumulative translation adjustment of $779,000, previously recognized under accumulated other comprehensive income (loss), was included as a component of the loss calculation for the sale of EWRS Turkey, reported in the statement of operations for the year ended 2014.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations – Based on guidance provided in accordance with ASU No. 2014-08 Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), the Company has analyzed the factors that define a discontinued operation and determined that the sale of EWRS Turkey is considered the sale of a significant component, but does not represent a major shift in the business, and therefore is not a discontinued operation.
	Effective May 31, 2014 (with closing occurring June 10, 2014) the Company sold EWRS Turkey for EUR 4.2 million (approximately $6.0M). The proceeds were used to reduce outstanding debt and the excess was cash to the Company of $768,000. Cash transactions were recorded for the time period June 1 to June 10, 2014, the date of closing. The Company recorded a loss on sale of subsidiary of $572,000. The Company is also eligible for an earn-out in fiscal years 2014 and 2015 based on future revenue derived from the units sold to Euromedic. It is not practicable to estimate the revenue from the earn-outs at this time and therefore no amounts have been recorded as of December 31, 2014
Earnings Per Share, Policy [Policy Text Block]	Earnings per share – Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options or warrants. The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2014, 2013 and 2012.
		2014			2013			2012
	Numerator for basic and diluted (loss) earnings per share	$	-952,000		$	-312,000		$	38,000
	Denominator:
	Denominator for basic (loss) earnings per share – weighted-average shares		5,028,000			4,608,000			4,609,000
	Effect of dilutive securities
	Employee stock options/restricted stock units		3,000			3,000			3,000
	Denominator for diluted (loss) earnings per share – adjusted weighted- average shares		5,031,000			4,611,000			4,612,000
	(Loss) earnings per common share- basic	$	-0.19		$	-0.07		$	0.01
	(Loss) earnings per common share- diluted	$	-0.19		$	-0.07		$	0.01
	In 2014, options outstanding to purchase 633,000 shares of common stock at an exercise price range of $2.43 - $6.16 per share, and warrants to purchase 200,000 sharesof common stock, issued with promissory notes, at an exercise price of $2.20, were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
	In 2013, options outstanding to purchase 576,000 shares of common stock at an exercise price range of $2.30 - $6.50 per share were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
	In 2012, options outstanding to purchase 588,000 shares of common stock at an exercise price range of $2.76 - $6.50 per share were not included in the calculation of diluted earnings per share because they would be anti-dilutive.
Segment Reporting, Policy [Policy Text Block]	Business segment information - The Company, which engages in the business of leasing radiosurgery and radiation therapy equipment to health care providers, has one reportable segment, Medical Services Revenue.
	The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment:
		2014		2013		2012
	Medical services revenues
	Domestic	97	%	91	%	93	%
	Foreign	3	%	9	%	7	%
	Total	100	%	100	%	100	%
		2014		2013
	Property and equipment, net
	Domestic	94	%	84	%
	Foreign	6	%	16	%
	Total	100	%	100	%
Nonmonetary transactions [Policy Text Block]	Nonmonetary transactions – Based on guidance provided in accordance with ASC No. 845 Nonmonetary Transactions (“ASC 845”), barter transactions with commercial substance are recorded at the estimated fair value of the products exchanged, unless the products received have a more readily determinable estimated fair value. The Company entered into a lease agreement in December 2014 where the lessee exchanged certain medical services equipment for a nominal amount and more beneficial contract terms related to the revenue sharing arrangement. The Company estimated and recorded the fair value of the equipment received and recognized deferred revenue. The fair value of the equipment received during the year ended December 31, 2014 was $700,000.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to operations in the period in which management determines such impairment. No such impairment has been noted as of December 31, 2014 and 2013.
Reclassification, Policy [Policy Text Block]	Out-of-Period Adjustment: During the fourth quarter of 2014, the Company reclassified $400,000 to non-controlling interests and $235,000 to additional paid-in capital that were incorrectly classified as liabilities. The corrections were not material to any previously reported financial periods or to the year ended December 31, 2014.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued accounting pronouncements – In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASU 2014-09"), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern ("ASU 2014-15 "). ASU 2014-15 provides guidance in GAAP about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for reporting periods ending after December 15, 2016. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to affect the Company's consolidated financial position, results of operations or cash flows.

ACCOUNTING_POLICIES_Tables

ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of December 31, 2014 and December 31, 2013 were as follows (in thousands):
												Carrying
		Level 1			Level 2			Level 3		Total		Value
	31-Dec-14
	Assets:
	Cash, cash equivalents, restricted cash	$	1,109		$	-		$	-	$	1,109	$	1,109
	Certificate of deposit		9,000			-					9,000		9,000
	Investment in equity securities		-			-			330		330		2,709
	Total	$	10,109		$	-		$	330	$	10,439	$	12,818
	Liabilities
	Advances on line of credit		8,780			-			-		8,780		8,780
	Debt obligations		-			10,658			-		10,658		10,591
	Total	$	8,780		$	10,658		$	-	$	19,438	$	19,371
	31-Dec-13
	Assets:
	Cash, cash equivalents, restricted cash	$	1,959		$	-		$	-	$	1,959	$	1,959
	Certificate of deposit		9,000			-			-		9,000		9,000
	Investment in equity securities		-			-			300		300		2,701
	Total	$	10,959		$	-		$	300	$	11,259	$	13,660
	Liabilities
	Advances on line of credit		8,840			-			-		8,840		8,840
	Debt obligations		-			15,082			-		15,082		15,544
	Total	$	8,840		$	15,082		$	-	$	23,922	$	24,384
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2014, 2013 and 2012.
		2014			2013			2012
	Numerator for basic and diluted (loss) earnings per share	$	-952,000		$	-312,000		$	38,000
	Denominator:
	Denominator for basic (loss) earnings per share – weighted-average shares		5,028,000			4,608,000			4,609,000
	Effect of dilutive securities
	Employee stock options/restricted stock units		3,000			3,000			3,000
	Denominator for diluted (loss) earnings per share – adjusted weighted- average shares		5,031,000			4,611,000			4,612,000
	(Loss) earnings per common share- basic	$	-0.19		$	-0.07		$	0.01
	(Loss) earnings per common share- diluted	$	-0.19		$	-0.07		$	0.01
Schedule of Domestic and Foreign Break out Percentages [Table Text Block]	The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment:
		2014		2013		2012
	Medical services revenues
	Domestic	97	%	91	%	93	%
	Foreign	3	%	9	%	7	%
	Total	100	%	100	%	100	%
		2014		2013
	Property and equipment, net
	Domestic	94	%	84	%
	Foreign	6	%	16	%
	Total	100	%	100	%

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following:
		DECEMBER 31,
		2014		2013
	Medical equipment and facilities	$	82,151,000	$	86,712,000
	Office equipment		721,000		749,000
	Deposits and construction in progress		8,736,000		4,719,000
	Deposits towards purchase of proton beam systems		5,000,000		3,000,000
			96,608,000		95,180,000
	Accumulated depreciation		-46,572,000		-43,799,000
	Net property and equipment	$	50,036,000	$	51,381,000

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following are contractual maturities of long-term debt by year at December 31, 2014:
	Year ending December 31,	Principal		Interest
	2015	$	2,053,000	$	654,000
	2016		2,698,000		525,000
	2017		2,669,000		369,000
	2018		1,546,000		159,000
	2019		891,000		85,000
	Thereafter		867,000		58,000
		$	10,724,000	$	1,850,000

OBLIGATIONS_UNDER_CAPITAL_LEAS1

OBLIGATIONS UNDER CAPITAL LEASES (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum lease payments, together with the present value of the net minimum lease payments under capital leases at December 31, 2014, are summarized as follows:
		Net Present Value
		of Minimum
		Lease Payments
	Year ending December 31,
	2015	$	5,108,000
	2016		4,783,000
	2017		4,282,000
	2018		2,714,000
	2019		1,415,000
	Thereafter		380,000
	Total capital lease payments		18,682,000
	Less imputed interest		2,389,000
			16,293,000
	Less current portion		4,103,000
		$	12,190,000

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2014 and 2013 are as follows:
		DECEMBER 31,
		2014		2013
	Deferred tax liabilities:
	Property and equipment	$	-7,145,000	$	-7,201,000
	Total deferred tax liabilities		-7,145,000		-7,201,000
	Deferred tax assets:
	Net operating loss carryforwards		3,424,000		3,607,000
	Accruals and allowances		173,000		240,000
	Tax credits		319,000		318,000
	Other – net		235,000		101,000
	Capital loss carryover		437,000		-
	Total deferred tax assets		4,588,000		4,266,000
	Valuation allowance		-549,000		-95,000
	Deferred tax assets net of valuation allowance		4,039,000		4,171,000
	Net deferred tax liabilities	$	-3,106,000	$	-3,030,000
Condensed Financial Statements [Table Text Block]	These amounts are presented in the financial statements as follows:
		DECEMBER 31,
		2014		2013
	Current deferred tax assets	$	367,000	$	342,000
	Deferred income taxes (non-current)		-3,473,000		-3,372,000
		$	-3,106,000	$	-3,030,000
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes consist of the following:
		YEARS ENDED DECEMBER 31,
			2014		2013		2012
	Current:
	Federal	$	-	$	-	$	18,000
	State		54,000		23,000		65,000
	Foreign		-		-		-
	Total current		54,000		23,000		83,000
	Deferred:
	Federal		-131,000		184,000		95,000
	State		40,000		12,000		-41,000
	Foreign		166,000		-135,000		-30,000
	Total deferred		75,000		61,000		24,000
		$	129,000	$	84,000	$	107,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (34% in 2014, 2013 and 2012) to income before taxes as follows:
		YEARS ENDED DECEMBER 31,
		2014		2013		2012
	Computed expected federal income tax	$	-280,000	$	-92,000	$	49,000
	State income taxes, net of federal benefit		66,000		120,000		38,000
	Non-deductible expenses		21,000		28,000		24,000
	Change in valuation allowance		416,000		-68,000		-61,000
	Other		-94,000		96,000		57,000
		$	129,000	$	84,000	$	107,000

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Changes in stock options outstanding under the Incentive Compensation Plans during 2014 are as follows :
							Weighted
				Weighted			Average
				Average			Remaining	Aggregate
		Number		Exercise			Contractual	Intrinsic
	Options	of Options		Price			Term (Years)	Value
	Balance at December 31, 2013	601,000		$	3.5
	Granted	522,000		$	2.89
	Exercised	-		$	-
	Forfeited	-464,000		$	3.34
	Balance at December 31, 2014	659,000		$	3.13		5.57	$	-
	Exercisable at December 31, 2014	123,000		$	4.25		2.15	$	-
Schedule of Nonvested Share Activity [Table Text Block]	A summary of the status of the Company’s non-vested shares as of December 31, 2014, and changes during the year ended December 31, 2014 is presented below:
				Weighted
				Average
		Number		Grant-Date
	Nonvested Shares	of Options		Fair Value
	Nonvested at December 31, 2013	26,000		$	1.25
	Granted	522,000		$	1.23
	Vested	-12,000		$	1.14
	Forfeited	-		$	-
	Nonvested at December 31, 2014	536,000		$	1.23
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the Company’s option grants under the Plan in 2014, 2013 and 2012 was estimated using the following assumptions:
		2014		2013		2012
	Expected life (years)	7		7		7
	Expected forfeiture rate	0	%	0	%	0.0 -  4.0	%
	Expected volatility	40	%	49	%	40 - 45	%
	Dividend yield	0	%	0	%	0	%
	Risk-free interest rate	2	%	2.6 - 3.0	%	1.7	%

OPERATING_LEASES_Tables

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum payments under non-cancelable operating leases, net of expected sublease income, having initial terms of more than one year consisted of the following:
	Year ending December 31,
	2015	$	114,000
	2016		61,000
	Thereafter		-
		$	175,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]
		Commitment		Cash Deposits
	Proton Beam Units	$	38,600,000	$	5,000,000
	Gamma Knife Units		6,834,000		2,784,000
	Total Commitments	$	45,434,000	$	7,784,000

ACCOUNTING_POLICIES_Details

ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets, Carrying Value:
Cash, cash equivalents, restricted cash, Carrying Value	$1,109,000	$1,959,000
Certificate of deposit, Carrying Value	9,000,000	9,000,000
Investment in equity securities, Carrying Value	2,709,000	2,701,000
Total, Carrying Value	12,818,000	13,660,000
Liabilities, Carrying Value
Advances on line of credit, Carrying Value	0	8,840,000
Debt obligations, Carrying Value	10,591,000	15,544,000
Total, Carrying Value	19,371,000	24,384,000
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	1,109,000	1,959,000
Certificate of deposit, Fair Value	9,000,000	9,000,000
Investment in equity securities, Fair Value	330,000	300,000
Total, Fair Value	10,439,000	11,259,000
Liabilities, Fair Value
Advances on line of credit, Fair Value	8,780,000	8,840,000
Debt obligations, Fair Value	10,658,000	15,082,000
Total, Fair Value	19,438,000	23,922,000
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	1,109,000	1,959,000
Certificate of deposit, Fair Value	9,000,000	9,000,000
Total, Fair Value	10,109,000	10,959,000
Liabilities, Fair Value
Advances on line of credit, Fair Value	8,780,000	8,840,000
Total, Fair Value	8,780,000	8,840,000
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Total, Fair Value	0	0
Liabilities, Fair Value
Debt obligations, Fair Value	10,658,000	15,082,000
Total, Fair Value	10,658,000	15,082,000
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Investment in equity securities, Fair Value	330,000	300,000
Total, Fair Value	330,000	300,000
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	$0	$0

ACCOUNTING_POLICIES_Details_1

ACCOUNTING POLICIES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Line Items]
Numerator for basic and diluted (loss) earnings per share	($952,000)	($312,000)	$38,000
Denominator:
Denominator for basic (loss) earnings per share - weighted-average shares	5,028,000	4,608,000	4,609,000
Employee stock options/restricted stock units	3,000	3,000	3,000
Denominator for diluted (loss) earnings per share - adjusted weighted- average shares	5,031,000	4,611,000	4,612,000
(Loss) earnings per common share- basic (in dollars per share)	($0.19)	($0.07)	$0.01
(Loss) earnings per common share- diluted (in dollars per share)	($0.19)	($0.07)	$0.01

ACCOUNTING_POLICIES_Details_2

ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	100.00%
Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%
Domestic [Member] | Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	97.00%	91.00%	93.00%
Domestic [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	94.00%	84.00%
Foreign [Member] | Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	3.00%	9.00%	7.00%
Foreign [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	6.00%	16.00%

ACCOUNTING_POLICIES_Details_Te

ACCOUNTING POLICIES (Details Textual)

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Jun. 10, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

USD ($)

USD ($)

USD ($)

Noncontrolling Interest [Member]

Additional Paid-in Capital [Member]

EWRS [Member]

EWRS [Member]

EWRS [Member]

Sale of EWRS Turkey [Member]

Certificates of Deposit [Member]

Certificates of Deposit [Member]

Mevion Medical Systems Inc [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Accounting Policies [Line Items]

Line of Credit Facility, Maximum Amount Outstanding During Period

$9,000,000

$9,000,000

$9,000,000

$9,000,000

Interest Costs Capitalized

371,000

390,000

196,000

Property Subject to or Available for Operating Lease, Net, Total

82,151,000

86,712,000

Property Subject to or Available for Operating Lease, Accumulated Depreciation

46,138,000

43,805,000

Cost Method Investments

2,709,000

2,701,000

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

633,000

576,000

588,000

Foreign Currency Transaction Gain, before Tax

161,000

1,174,000

132,000

Cost Method Investment Interest Percentage

0.77%

Property, Plant and Equipment, Estimated Useful Lives

15

3

Stock Options Exercise Price

$6.16

$6.50

$6.50

$2.43

$2.30

$2.76

Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)

779,000

Payments for (Proceeds from) Investments

6,000,000

4,200,000

Gain (Loss) on Disposition of Stock in Subsidiary

-572,000

0

0

572,000

Warrants Issued With Promissory Notes During The Period

200,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$2.20

Proceeds from Divestiture of Interest in Consolidated Subsidiaries

768,000

0

0

768,000

Fair Value of Assets Acquired

700,000

0

0

Asset Impairment Charges

0

Advertising Expense

155,000

119,000

103,000

Prior Period Reclassification Adjustment

$400,000

$235,000

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$96,608,000	$95,180,000
Accumulated depreciation	-46,572,000	-43,799,000
Net property and equipment	50,036,000	51,381,000
Medical Equipment and Facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	82,151,000	86,712,000
Accumulated depreciation	-11,269,000	-9,858,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	721,000	749,000
Deposits and Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	8,736,000	4,719,000
Deposits Towards Purchase of Proton Beam Systems [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$5,000,000	$3,000,000

PROPERTY_AND_EQUIPMENT_Details1

PROPERTY AND EQUIPMENT (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$46,572,000	$43,799,000
Medical Equipment and Facilities [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	29,548,000	30,538,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	11,269,000	9,858,000
Radiation Oncology Physician Group [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	400,000
Three Mevion S250 Proton Beam Radiation Therapy [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	$5,000,000

INVESTMENT_IN_EQUITY_SECURITIE1

INVESTMENT IN EQUITY SECURITIES (Details Textual) (USD $)	12 Months Ended	0 Months Ended		1 Months Ended
	Dec. 31, 2014	Sep. 05, 2007	Apr. 10, 2006	Jan. 31, 2012	Oct. 31, 2008	Dec. 31, 2013	Jun. 30, 2013
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	$2,709,000					$2,701,000
Investment Percentage in Common Stock	0.77%
Unrealized Gain (Loss) on Investments	2,400,000
Additional Cost Method Investments				70,000
Stockholders' Equity, Reverse Stock Split	In mid-2011, Mevion performed a reverse stock split of all shares in which 100 shares were converted to one share.
Series B Convertible Preferred Stock [Member]
Schedule of Cost-method Investments [Line Items]
Conversion of Stock, Shares Issued		588,000	2,353,000
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	10,000,000	617,000	2,000,000	45,000,000			55,000,000
Initially Funded Percentage				55.00%
Remaining Funded Percentage				45.00%
Proceeds from Sale of Other Investments					$65,000,000

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	Dec. 31, 2014
Principal
2015	$2,053,000
2016	2,698,000
2017	2,669,000
2018	1,546,000
2019	891,000
Thereafter	867,000
Long-term Debt	10,724,000
Interest
2015	654,000
2016	525,000
2017	369,000
2018	159,000
2019	85,000
Thereafter	58,000
Interest	$1,850,000

LONGTERM_DEBT_Details_Textual

LONG-TERM DEBT (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Long-term Debt, Description	payable in 36 to 84 fully amortizing monthly installments, mature between December 2015 and November 2021
Long-term Debt	$10,724,000
Proceeds from Notes Payable	1,000,000	0	0
Fair Value Of Warrants Issued With Promissory Notes	145,000	0	0
Maximum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	7.48%
Minimum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	3.95%
Eleven Notes [Member]
Debt Instrument [Line Items]
Long-term Debt		15,544,000
Eight Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	$9,724,000

OBLIGATIONS_UNDER_CAPITAL_LEAS2

OBLIGATIONS UNDER CAPITAL LEASES (Details) (USD $)	Dec. 31, 2014
Capital Lease Obligations [Line Items]
2015	$5,108,000
2016	4,783,000
2017	4,282,000
2018	2,714,000
2019	1,415,000
Thereafter	380,000
Total capital lease payments	18,682,000
Less imputed interest	2,389,000
Gross Minimum Lease Payments	16,293,000
Less current portion	4,103,000
Net Minimum Lease Payments	$12,190,000

OBLIGATIONS_UNDER_CAPITAL_LEAS3

OBLIGATIONS UNDER CAPITAL LEASES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Capital Lease Obligations [Line Items]
Description of Lessee Leasing Arrangements, Capital Leases	payable in 60 to 84 monthly installments, and mature between July 2015 and May 2020.
Maximum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate		9.50%
Minimum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate	5.15%
Nine Obligations [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligations	18,279,000	20,680,000

LINE_OF_CREDIT_Details_Textual

LINE OF CREDIT (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Amount Outstanding	$9,000,000	$9,000,000
Debt Instrument, Interest Rate Terms	the banks prime rate minus 0.5 percentage point, or alternatively at the Companys discretion, the LIBOR rate plus 1.0 percentage point.
Debt, Weighted Average Interest Rate	1.40%
Long-term Line of Credit, Noncurrent	$0	$8,840,000
Line of Credit Facility, Expiration Date	31-Dec-14

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax liabilities:
Property and equipment	($7,145,000)	($7,201,000)
Total deferred tax liabilities	-7,145,000	-7,201,000
Deferred tax assets:
Net operating loss carryforwards	3,424,000	3,607,000
Accruals and allowances	173,000	240,000
Tax credits	319,000	318,000
Other - net	235,000	101,000
Capital loss carryover	437,000	0
Total deferred tax assets	4,588,000	4,266,000
Valuation allowance	-549,000	-95,000
Deferred tax assets net of valuation allowance	4,039,000	4,171,000
Net deferred tax liabilities	($3,106,000)	($3,030,000)

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Current deferred tax assets	$367,000	$342,000
Deferred income taxes (non-current)	-3,473,000	-3,372,000
Total deferred tax liabilities	($3,106,000)	($3,030,000)

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$0	$0	$18,000
State	54,000	23,000	65,000
Foreign	0	0	0
Total current	54,000	23,000	83,000
Deferred:
Federal	-131,000	184,000	95,000
State	40,000	12,000	-41,000
Foreign	166,000	-135,000	-30,000
Total deferred	76,000	59,000	25,000
Income Tax Expense (Benefit)	$129,000	$84,000	$107,000

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Computed expected federal income tax	($280,000)	($92,000)	$49,000
State income taxes, net of federal benefit	66,000	120,000	38,000
Non-deductible expenses	21,000	28,000	24,000
Change in valuation allowance	416,000	-68,000	-61,000
Other	-94,000	96,000	57,000
Income Tax Expense (Benefit)	$129,000	$84,000	$107,000

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	34.00%	34.00%	34.00%
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$9,518,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	1,540,000
Operating Loss Carry Forward Expiration Dates	expire between 2019 and 2033
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$416,000	($68,000)	($61,000)
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carry Forward Expiration Dates	begin to expire in 2014 and 2029

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning balance	601,000
Number of Options, Granted	522,000
Number of Options, Exercised	0
Number of Options, Forfeited	-464,000
Number of Options, Ending balance	659,000
Number of Options, Exercisable at December 31, 2014	123,000
Weighted Average Exercise Price, Beginning balance	$3.50
Weighted Average Exercise Price, Granted	$2.89
Weighted Average Exercise Price - Exercised	$0
Weighted Average Exercise Price, Forfeited	$3.34
Weighted Average Exercise Price, Ending balance	$3.13
Weighted Average Exercise Price, Exercisable at December 31, 2014	$4.25
Weighted Average Remaining Contractual Term (Years), Balance at December 31, 2014	5 years 6 months 25 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2014	2 years 1 month 24 days
Aggregate Intrinsic Value, Balance at December 31, 2014	$0
Aggregate Intrinsic Value, Exercisable at December 31, 2014	$0

SHAREHOLDERS_EQUITY_Details_1

SHAREHOLDERS' EQUITY (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Shareholders Equity [Line Items]
Nonvested, Number of Options, Outstanding	26,000
Nonvested, Number of Options, Granted	522,000
Nonvested, Number of Options, Vested	-12,000
Nonvested, Number of Options, Vested	0
Nonvested, Number of Options, Outstanding	536,000	26,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$1.25
Weighted Average Grant-Date Fair Value, Nonvested, Granted	$1.23	$1.28	$1.60
Weighted Average Grant-Date Fair Value, Nonvested, Vested	$1.14
Weighted Average Grant-Date Fair Value, Nonvested, Forfeited	$0
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$1.23	$1.25

SHAREHOLDERS_EQUITY_Details_2

SHAREHOLDERS' EQUITY (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	7 years	7 years	7 years
Expected forfeiture rate	0.00%	0.00%
Expected forfeiture rate - Minimum			0.00%
Expected forfeiture rate - Maximum			4.00%
Expected volatility	40.00%	49.00%
Expected volatility - Minimum			40.00%
Expected volatility - Maximum			45.00%
Dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate - Minimum		2.60%
Risk-free interest rate - Maximum		3.00%
Risk-free interest rate	2.00%		1.70%

SHAREHOLDERS_EQUITY_Details_Te

SHAREHOLDERS' EQUITY (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2010	Dec. 31, 2001
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$1.23	$1.28	$1.60
Share Based Compensation Arrangement By Share Based Payment Award Remaining Number Of Shares Available For Grant	738,000
Stock Repurchase Program, Number of Shares Authorized to be Repurchased					1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000
Stock Repurchased During Period, Shares	1,000		9,000
Allocated Share-based Compensation Expense	$51,000	$88,000	$74,000
Incentive Compensation Plan [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				1,630,000
Provision For Reduction Of Reserved Shares				1.59
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award				2,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	138,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$2.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	6,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	732,000
Employee Benefits and Share-based Compensation, Total	7,000
Offsetting Tax Benefit	1,900
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	2,100
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	5 years
Weighted Average Number of Shares, Restricted Stock	3,000
Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				500
Incentive Compensation Plan [Member] | Non Employee Directors and Corporate Secretary [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	23,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross	3,000
Retainer Fees [Member]
Class of Stock [Line Items]
Employee Benefits and Share-based Compensation, Total	$80,000
Retainer Fees [Member] | Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	115,000
Retainer Fees [Member] | Incentive Compensation Plan [Member] | Non Employee Directors and Corporate Secretary [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	30,000

RETIREMENT_PLAN_Details_Textua

RETIREMENT PLAN (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Cost Recognized	$43,000	$41,000	$41,000

OPERATING_LEASES_Details

OPERATING LEASES (Details) (USD $)	Dec. 31, 2014
Operating Leased Assets [Line Items]
2015	$114,000
2016	61,000
Thereafter	0
Total Future Minimum Payments Due	$175,000

OPERATING_LEASES_Details_Textu

OPERATING LEASES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$301,000	$549,000	$438,000
Operating Leases Cumulative Loss		115,000
Operating Leases, Rent Expense, Net	$173,000	$116,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Long-term Purchase Commitment [Line Items]
Total Commitment	$45,434,000
Total Cash Deposits	7,784,000
Proton Beam Units [Member]
Long-term Purchase Commitment [Line Items]
Total Commitment	38,600,000
Total Cash Deposits	5,000,000
Gamma Knife Units [Member]
Long-term Purchase Commitment [Line Items]
Total Commitment	6,834,000
Total Cash Deposits	$2,784,000

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	$45,434,000
Long Term Purchase Commitment Deposits For Future Purchase	7,784,000
Long-term Purchase Commitment, Additional Amount	$9,000,000
Long Term Purchase Commitment Due Discription	Approximately $27,000,000 of these commitments are not expected to start becoming due until 2016.

NOTE_WARRANT_COMMON_STOCK_PURC1

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Common Stock, Shares, Issued	5,361,000	4,609,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$2.20
Mevion Medical Systems Inc [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Cash Payments	$1,000,000
Private Placement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	100,000
Proceeds from Issuance of Private Placement	220,000
Common Stock, Value, Subscriptions	1,220,000
Stock Issued During Period, Shares, New Issues	650,000
Stock Issued During Period, Value, New Issues	1,600,000
Note and Warrant Purchase Agreement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Debt Instrument, Face Amount	$1,000,000
Common Stock, Shares, Issued	200,000
Debt Instrument, Interest Rate, Stated Percentage	15.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$2.20
Debt Instrument, Maturity Date	22-Oct-17

SIGNIFICANT_RELATED_PARTY_TRAN1

SIGNIFICANT RELATED PARTY TRANSACTIONS (Details Textual)	Dec. 31, 2014
GKF Subsidiary [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	81.00%
Equity Method Investment, Ownership Percentage	70.00%
U.S. Subsidiary Of Elekta [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	19.00%
EWRS LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	70.00%
EMKA [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	30.00%

MAJOR_CUSTOMERS_Details_Textua

MAJOR CUSTOMERS (Details Textual) (Total Revenue [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Concentration Risk, Percentage	100.00%	100.00%	100.00%
Customer One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	9.00%	10.00%	13.00%
Customers Two [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	9.00%	10.00%	11.00%